Comprehensive genomic profiling of combined small cell lung cancer

Background: Combined small cell lung cancer (CSCLC) is an uncommon and heterogeneous subtype of small cell lung cancer (SCLC). However, there is limited data concerning the different molecular changes and clinical features in CSCLC compared to pure SCLC. Methods: The clinical and pathological charac...

Full description

Autores:
Zhang, Jing
Zhang, Liping
Luo, Jie
Ge, Tao
Fan, Pengyu
Sun, Liangdong
Hou, Likun
Li, Junqiang
Yu, Huansha
Wu, Chunxiao
Zhu, Yuming
Wu, Chunyan
Jiang, Gening
Troncone, Giancarlo
Malhotra, Jyoti
Okuda, Katsuhiro
Santarpia, Mariacarmela
Zamarchi, Rita
Goto, Taichiro
Cardona, Andrés F.
Xu, Jianfang
Chen, Qiankun
Zhang, Zhonghong
Zhang, Peng
Tipo de recurso:
Article of journal
Fecha de publicación:
2021
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
eng
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/8686
Acceso en línea:
http://hdl.handle.net/20.500.12495/8686
https://doi.org/10.21037/TLCR-20-1099
Palabra clave:
Cáncer de pulmón de células pequeñas combinado (CPCP)
Cáncer de pulmón de células pequeñas (CPCP)
Perfiles genómicos completos
Secuenciación genética dirigida
Combined small cell lung cancer (CSCLC)
Small cell lung cancer (SCLC)
Comprehensive genomic profiling
Targeted gene sequencing
Rights
closedAccess
License
Acceso cerrado
Description
Summary:Background: Combined small cell lung cancer (CSCLC) is an uncommon and heterogeneous subtype of small cell lung cancer (SCLC). However, there is limited data concerning the different molecular changes and clinical features in CSCLC compared to pure SCLC. Methods: The clinical and pathological characteristics of pure SCLC and CSCLC patients were analyzed. Immunohistochemistry and microdissection were performed to isolate the CSCLC components. Further molecular analysis was carried out by next-generation sequencing (NGS) in 12 CSCLC and 30 pure SCLC. Results: There were no significant differences in clinical features between CSCLC and pure SCLC. Overall survival (OS) of CSCLC patients was worse than pure SCLC (P=0.005). NGS results indicated that TP53 and RB1 were the most frequently mutated genes in both CSCLC (83.33% and 66.67%) and pure SCLC (80.00% and 63.33%) groups. However, less than 10% common mutations were found in both CSCLC and pure SCLC. When analyzing the data of SCLC and non-small cell lung cancer (NSCLC) components of CSCLC, more than 50% common mutations, and identical genes with mutations were detected. Moreover, there were also common biological processes and signaling pathways identified in CSCLC and pure SCLC, in addition to SCLC and NSCLC components. Conclusions: There were no significant differences in terms of clinical features between CSCLC and pure SCLC. However, the prognosis for CSCLC was worse than pure SCLC. NGS analysis suggested that CSCLC components might derive from the same pluripotent single clone with common initial molecular alterations and subsequent acquisitions of other genetic mutations.